Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1739510 | 1.00 | GSR (0.44) | GSRTRPA1RIPK1ATML3MBTL1 | |
| SCHEMBL14984000 | 1.00 | GSR (0.44) | GSRTRPA1RIPK1ATML3MBTL1 | |
| SCHEMBL31201875 | 0.85 | CA2 (0.33) | SLC6A4LMNACA2SLC6A2 | |
| SCHEMBL5223462 | 0.83 | AOC3 (0.37) | TRPA1AOC3SLC6A4LMNACA2 | |
| SCHEMBL9063602 | 0.83 | AOC3 (0.43) | AOC3SLC6A4SLC6A2 | |
| SCHEMBL3386536 | 0.83 | TAAR1 (0.41) | AOC3SLC6A4CA2SLC6A2SLC6A3 | |
| SCHEMBL3386535 | 0.83 | TAAR1 (0.41) | AOC3SLC6A4CA2SLC6A2SLC6A3 | |
| SCHEMBL3386613 | 0.83 | TAAR1 (0.41) | AOC3SLC6A4CA2SLC6A2SLC6A3 | |
| SCHEMBL7446159 | 0.82 | RIPK1 (0.37) | TRPA1RIPK1AOC3SLC6A4LMNA | |
| SCHEMBL1741422 | 0.81 | CA2 (0.35) | RIPK1ATML3MBTL1AOC3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3214086-B1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | UBE INDUSTRIES (JP) | 2021-09-22 | — | — | EP | disclosed |
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | UBE INDUSTRIES, LTD. (JP) | 2021-04-06 | — | — | US | disclosed |
| CN-107074887-B | Substituted dihydropyrrolopyrazoles | 宇部兴产株式会社 | 2020-12-22 | — | — | CN | disclosed |
| US-10131679-B2 | Substituted dihydropyrrolopyrazole compound | UBE INDUSTRIES, LTD. (JP) | 2018-11-20 | — | — | US | disclosed |
| US-20170313727-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2017-11-02 | — | — | US | disclosed |
| EP-3214086-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | Ube Industries, Ltd. (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-5977374-A | 5-(4-hydroxy-OR 4-acetoxy-benzyl)-3- triphenylmethylthiazolidine-2,4-dione and method for producing same | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5635534-A | 1-PHENYL-2-(2-PHENYLOXY OR THIO)-1-METHYLETHYL)AMINOETHANOL DERIVATIVES; ALDOSE REDUCTASE INHIBITORS; NONTOXIC; ANTIDIABETIC,-OBESITY,-LIPEMIC AND HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-06-03 | — | — | US | disclosed |
| US-5576340-A | Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0543662-B1 | Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses | SANKYO CO (JP) | 1996-09-18 | — | — | EP | disclosed |
| EP-0543662-A2 | Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 1993-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313727-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | QDPR, CYP2D6, DCLK3 | GSR 1575/4885TRPA1 678/4885RIPK1 2230/4885 |
| US-10131679-B2 | Substituted dihydropyrrolopyrazole compound | QDPR, CYP2D6, DCLK3 | GSR 1575/4885TRPA1 678/4885RIPK1 2230/4885 |
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | QDPR, CYP2D6, KCNJ11 | GSR 1664/4885TRPA1 518/4885RIPK1 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.